LifeVantage Corp (OQ:LFVN)

Sector:  Healthcare Industry:  Pharmaceuticals
 
See Regulatory Filings on SEC
Company Contact
Address: 3300 TRIUMPH BLVD, SUITE 700
LEHI UT 84043
Tel: N/A
Website: https://www.lifevantage.com
IR: See website
<
Key People
Steven R. Fife
President, Chief Executive Officer, Director 		Carl Aure
Chief Financial Officer 		Julie Boyster
Chief Marketing Officer
Alissa Neufeld
General Counsel, Corporate Secretary 		   
Business Overview
LifeVantage Corporation is engaged in the identification, research, development, formulation and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. The Company's dietary supplements include its flagship Protandim family of products, LifeVantage Omega+, ProBio, IC Bright, and Daily Wellness dietary supplements. The Protandim product line includes Protandim NRF1 Synergizer, Protandim Nrf2 Synergizer, and Protandim NAD Synergizer. TrueScience is its line of skin, hair, bath and body, and targeted relief products. The Company also markets and sells Petandim, its companion pet supplement formulated to combat oxidative stress in dogs; Axio, its nootropic energy drink mixes, and PhysIQ, its smartweight management system, which includes PhysIQ Fat Burn and PhysIQ Prebiotic, all formulated to aid in weight management.
Financial Overview
For the six months ended 31 December 2023, LifeVantage Corp revenues decreased 2% to $103M. Net loss decreased 94% to $27K. Revenues reflect Asia/Pacific & Europe segment decrease of 13% to $25.4M. Lower net loss reflects Commissions and incentives decrease of 7% to $44.2M (expense), Interest expense, net increase from $32K to $276K (income). Dividend per share increased from $0.06 to $0.07.
Employees: 248 as of Jun 30, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $68.89M as of Dec 31, 2023
Annual revenue (TTM): $210.95M as of Dec 31, 2023
EBITDA (TTM): $7.34M as of Dec 31, 2023
Net annual income (TTM): $2.96M as of Dec 31, 2023
Free cash flow (TTM): $3.73M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 12,868,462 as of Jan 29, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.

Learn More